Ocean Biomedical

Ocean Biomedical Cash Conversion

The Cash Conversion Rate (OCF/Net Income) of Ocean Biomedical (OCEA) as of Nov 21, 2026 is 126.63 %. In the previous year, Cash Conversion Rate (OCF/Net Income) was 8.24 % — a change of 1,437.24% (higher).

Cash Conversion

126.63 %

YoY

1,437.24%

Last updated:

Cash Conversion Rate (OCF/Net Income) of Ocean Biomedical is 2024 126.63 % . Cash Conversion Rate (OCF/Net Income) of Ocean Biomedical was 2023 8.24 % . It decreases by 1,437.24% higher compared to the previous year.

The Ocean Biomedical Cash Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion
Date
Cash Conversion
Jan 1, 2019
27.59 USD
Jan 1, 2020
3.87 USD
Jan 1, 2021
1.69 USD
Jan 1, 2022
-132.16 USD
Jan 1, 2023
8.24 USD
Jan 1, 2024
126.63 USD
The Ocean Biomedical Cash Conversion history
YEARCash ConversionYoY
126.63 %+1,437.24%
8.24 %-106.23%
-132.16 %-7,924.38%
1.69 %-56.38%
3.87 %-85.96%
27.59 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Ocean Biomedical Stock analysis

What does Ocean Biomedical do? Ocean Biomedical, Inc. develops therapeutic products in oncology, fibrosis, infectious diseases, and inflammation. The company focuses on monoclonal antibodies like Chi3l1-targeting mAbs for non-small cell lung cancer and glioblastoma multiforme. It also offers malaria-related candidates including ODA-570, a vaccine targeting PfSEA-1 and PfGARP, ODA-611, a humanized mAb therapeutic for malaria, and ODA-579, a small molecule malaria therapeutic. These products are developed from research university and medical center assets to accelerate their commercialization. The company monetizes through the development and commercialization of its product candidates. Oncology and malaria-focused therapies represent key segments, with ODA-570, ODA-611, and ODA-579 targeting specific disease areas. Research universities and medical centers are primary collaborators for asset development, providing the foundation for Ocean Biomedical's pipeline. Ocean Biomedical's revenue streams derive from the progression of its therapeutic candidates through development stages. The firm's focus on oncology and malaria therapies drives its product portfolio, with specific candidates like ODA-570, ODA-611, and ODA-579 being central to its commercial strategy. The company accelerates the development of these assets to reach market readiness. Ocean Biomedical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Ocean Biomedical stock

Cash Conversion Rate (OCF/Net Income) of Ocean Biomedical is 126.63 % in 2024.

Cash Conversion Rate (OCF/Net Income) of Ocean Biomedical changed from 8.24 % to 126.63 %, representing a 1,437.24% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Rate (OCF/Net Income) Ocean Biomedical since 2006 – with annual values, charts, and detailed analysis.

Cash conversion measures how effectively net income converts to operating cash flow. Ratios above 100% indicate high-quality, cash-backed earnings.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Rate (OCF/Net Income)'s Ocean Biomedical with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Rate (OCF/Net Income)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Rate (OCF/Net Income).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Ocean Biomedical

All Key Metrics — Ocean Biomedical